In Vivo and in vitro antitumor activity of tomatine in hepatocellular carcinoma

Vista sencilla de ítem
dc.contributor.authorEcheverría, Cesar
dc.contributor.authorMartin, Aldo
dc.contributor.authorSimon, Felipe
dc.contributor.authorSalas, Cristian O.
dc.contributor.authorNazal, Mariajesus
dc.contributor.authorVarela, Diego
dc.contributor.authorPérez-Castro, Ramón A.
dc.contributor.authorSantibanez, Juan F.
dc.contributor.authorValdés-Valdés, Ricardo O.
dc.contributor.authorForero-Doria, Oscar
dc.contributor.authorEcheverría, Javier
dc.date.accessioned2023-03-30T18:09:42Z
dc.date.available2023-03-30T18:09:42Z
dc.date.issued2022-09
dc.descriptionIndexación: Scopuses
dc.description.abstractBackground: There is abundant ethnopharmacological evidence the uses of regarding Solanum species as antitumor and anticancer agents. Glycoalkaloids are among the molecules with antiproliferative activity reported in these species. Purpose: To evaluate the anticancer effect of the Solanum glycoalkaloid tomatine in hepatocellular carcinoma (HCC) in vitro (HepG2 cells) and in vivo models. Methods: The resazurin reduction assay was performed to detect the effect of tomatine on cell viability in human HepG2 cell lines. Programmed cell death was investigated by means of cellular apoptosis assays using Annexin V. The expression of cancer related proteins was detected by Western blotting (WB). Reactive oxygen species (ROS) and calcium were determined by 2,7-dichlorodihydrofluorescein diacetate and Fluo-4, respectively. Intrahepatic HepG2 xenograft mouse model was used to elucidate the effect of tomatine on tumor growth in vivo. Results and Discussion: Tomatine reduced HepG2 cell viability and induced the early apoptosis phase of cell death, consistently with caspase-3, -7, Bcl-2 family, and P53 proteins activation. Furthermore, tomatine increased intracellular ROS and cytosolic Ca+2 levels. Moreover, the NSG mouse xenograft model showed that treating mice with tomatine inhibited HepG2 tumor growth. Conclusion: Tomatine inhibits in vitro and in vivo HCC tumorigenesis in part via modulation of p53, Ca+2, and ROS signalling. Thus, the results suggest the potential cancer therapeutic use of tomatine in HCC patients. Copyright © 2022 Echeverría, Martin, Simon, Salas, Nazal, Varela, Pérez-Castro, Santibanez, Valdés-Valdés, Forero-Doria and Echeverría.es
dc.description.urihttps://www.frontiersin.org/articles/10.3389/fphar.2022.1003264/full
dc.identifier.citationFrontiers in PharmacologyOpen AccessVolume 139 September 2022 Article number 1003264es
dc.identifier.doi10.3389/fphar.2022.1003264
dc.identifier.issn1663-9812
dc.identifier.urihttps://repositorio.unab.cl/xmlui/handle/ria/48067
dc.language.isoenes
dc.publisherFrontiers Media S.A.es
dc.rights.licenseAtribución 4.0 Internacional (CC BY 4.0)
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/deed.es
dc.subjectAntitumoral activityes
dc.subjectApoptosises
dc.subjectCaspase pathwayses
dc.subjectHepatocellular carcinomaes
dc.subjectSolanum glycoalkaloidses
dc.subjectTomatinees
dc.titleIn Vivo and in vitro antitumor activity of tomatine in hepatocellular carcinomaes
dc.typeArtículoes
Archivos
Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Echeverria_C_In_Vivo_and_in_vitro_2022_Article.pdf
Tamaño:
2.43 MB
Formato:
Adobe Portable Document Format
Descripción:
TEXTO COMPLETO EN INGLES
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar
Colecciones
Fac.CV - Artículos de Revista